Aravali Securities & Finance will hold a meeting of the Board of Directors of the Company on 1 December 2025.

Bajaj Electricals has allotted 18,301 equity shares under ESOP on 24 November 2025. Post this allotment, the issued, subscribed and paid-up capital of the Company shall comprise of 11,53,88,440 equity shares of Rs.2 each fully paid-up amounting to Rs. 23,07,76,880/-.

Abbott India has received approval from the Central Government under Section 196 of the Companies Act, 2013 for the appointment of Kartik Rajendran (DIN: 09527717) as the Managing Director of the Company, for a period of 5 (five) years, with effect from 14 June 2025 to 13 June 2030.

G.G. Tronics India (GGT), a subsidiary of CG Power & Industrial Solutions, announced that the Company has made significant progress in the development and field validation of the Uniform Braking Algorithm and in defining braking parameters across multiple locomotive classes of Indian Railways. This requirement, introduced by the Centre of Excellence (COE) and RDSO, aims to ensure consistent braking performance across vendors. This advanced braking methodology is poised to become a benchmark for future locomotive operations.

G.G. Tronics India had received an order from Chittaranjan Locomotive Works for the supply of Loco Kavach systems under the Developmental Category in November 2024. The delivery period was 12 months subject to completion of product development, Independent Safety Assessment (ISA), RDSO approval, and full compliance with Version 4.0 specifications. The ISA and RDSO approval activities are now in their final stages. Due to these approval timelines, the supply could not be initiated within the stipulated delivery period and order stands cancelled.

GGT will continue to remain qualified for upcoming tenders under the Developmental Category. With approvals expected in the coming months, the company will also be eligible to participate in bulk procurement, offering the enhanced capabilities of the Universal Braking Algorithm along with full Version 4.0.

Hindustan Construction Company will hold a meeting of the Board of Directors of the Company on 26 November 2025.

Surya Roshni has received an order of Rs 105.18 crore from an engineering and infrastructure company for supply of spiral pipes with external 3 LPE coating.

Rollatainers announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 16 December 2025.

Eurogrip, India's leading two-and three-wheeler tyres from TVS Srichakra, showcased its premium product portfolio of tyres at two major international platforms, Expo Moto International Trade Show, Mexico City and Colombo Motor Show in Sri Lanka. This participation signals Eurogrip's expanding presence in Latin American and South Asian markets.

At the Expo Moto International Trade Show, Mexico, Eurogrip showcased its comprehensive range of 2-wheeler tyres including leading patterns like Roadhound, Protorq Extreme, Trailhound STR, Trailhound SCR, Terrabite DB+ and Bee Connect giving customers, dealers, and global partners an enriched experience of Eurogrip's R&D and advanced tyre technology.

At the Colombo Motor Show 2025 being held at Colombo, Eurogrip displayed its most-sought after radial tyre offering Protorq Extreme along with other world-class products like Terrabite DB+, Bee Connect, Bee Sport, Climber XC and Sportorq.

Western Ministil will hold a meeting of the Board of Directors of the Company on 26 November 2025.

Dr Reddys Laboratories announced that the European Commission (EC) has granted marketing authorization for AVT03, a biosimilar of Prolia® (denosumab) and Xgeva® (denosumab).

Prolia® is a prescription medicine used to treat osteoporosis in women who have been through menopause and in men who are at increased risk of fractures, bone loss linked to hormone ablation in men with prostate cancer at increased risk of fractures and bone loss associated with long-term treatment with systemic glucocorticoid. Xgeva® is a prescription medicine used to prevent bone complications in adults with advanced cancer involving bone and for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone.

The EC decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) adopted in September 2025 and was based on a totality of evidence, including analytical comparisons, pharmacokinetic and pharmacodynamic data, and outcomes from a confirmatory clinical trial. The EC decision is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway.

In May 2024, Dr. Reddy's and Alvotech entered into a license and supply agreement for the commercialization of AVT03. Under the agreement, Alvotech will develop and manufacture AVT03, while Dr. Reddy's is responsible for registration and commercialization in applicable markets, including the U.S. and Europe. Dr. Reddy's commercialization rights are exclusive for the U.S., and semi-exclusive for Europe and the UK. Upon approval Dr. Reddy's will offer the biosimilar under the tradenames Acvybra® (denosumab) 60 mg/mL solution for injection in a pre-filled syringe and Xbonzy® (denosumab) 70 mg/mL solution for injection in a vial.